Harmony Biosciences Holdings, Inc. Announces Preliminary, Unaudited Net Product Revenues for the Fourth Quarter and Full Year Ended December 31, 2024
January 13, 2025 at 08:05 am EST
Share
Harmony Biosciences Holdings, Inc. announced preliminary, unaudited net product revenues for the fourth quarter and full year ended December 31, 2024. For the quarter, the company reported net product revenue was approximately $201 million, compared to $168.4 million for the same period in 2023.
For the full year, the company reported net product revenue was approximately $714 million, compared to $582 million for the same period in 2023, representing ~23% growth in its fifth year on the market .
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company. It is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. Its WAKIX is developed for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy and treatment of cataplexy in adult patients with narcolepsy. It also provides HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist that targets MCH neurons in the brain. It also develops ZYN002, a pharmaceutically manufactured synthetic cannabidiol. It is also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.